Last reviewed · How we verify
Prevention of COVID-19 in individuals 5 years of age and older as a booster dose
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of COVID-19 in individuals 5 years of age and older as a booster dose patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of COVID-19 in individuals 5 years of age and older as a booster dose treatment landscape brief
- Prevention of COVID-19 in individuals 5 years of age and older as a booster dose treatment updates RSS
Frequently asked questions about Prevention of COVID-19 in individuals 5 years of age and older as a booster dose
What drugs treat Prevention of COVID-19 in individuals 5 years of age and older as a booster dose?
Tracked treatments include Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1).
What is the treatment for Prevention of COVID-19 in individuals 5 years of age and older as a booster dose?
Standard treatment for Prevention of COVID-19 in individuals 5 years of age and older as a booster dose includes Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of COVID-19 in individuals 5 years of age and older as a booster dose patent cliff · Prevention of COVID-19 in individuals 5 years of age and older as a booster dose CI report
- Treatment: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing